Friday, 16 October 2026European Markets

ALTAREA Stock Bearish By 9% So Far On Monday

Loading stream...

altarea, a prominent force in the realm of low-carbon urban transformations, recently experienced a substantial decline in its stock value. there was a sharp decrease of 9.58% to eur90.60 on tuesday, occurring even as the cac 40 index rose by 0.49% to eur7,513.08, making it the third consecutive decline for the firm.

altarea's weekly performance and trends

the most recent closing rate for altarea was eur100.20. this figure signified a severe 33.11% decline from its 52-week high of eur149.80, pointing towards a worrisome downward trend amongst investors.

profitability of altarea amidst economic woes

an analysis of altarea's profitability can provide further insight into the firm's performance during these declining share prices. despite the issues at hand, the company has managed to boast an impressive trailing twelve-month earnings per share (eps) figure of eur15.83. however, given the current economic struggles, there is a marked level of uncertainty regarding the firm's future performance.

price to earnings ratio of altarea

altarea currently boasts a price to earnings (pe) ratio of 5.72. this figure suggests that investors are only putting in eur5.72 per share, a sum that is significantly smaller than what is seen with most companies. a higher pe ratio generally indicates that investors anticipate increased earnings in the future, but in the case of altarea, the low pe ratio might suggest reduced investor trust.

altarea's return on equity

altarea's return on equity (roe) is another crucial metric to consider. currently, this figure, which measures profitability related to shareholders' equity, is fairly low, coming in at 11.31 for the past twelve months.

altarea's trading volume trends

on another note, altarea has seen an increased trading volume recently, reaching 12493 - a figure that is considerably above the usual volume of 4120. this trend could suggest rising interest from traders even as prices continue to decline.

considering these figures and trends, prospective and current investors should carefully consider whether their risk tolerance aligns appropriately with the performance trends and financial health of altarea.

more news about altarea (alta.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com